DnB Asset Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
DnB Asset Management's CRSP Position: Q3 2026 in Review
DnB Asset Management opened a new position in CRISPR Therapeutics (CRSP) in Q3 2026: 4,038 shares worth $223K. The stake represents ﹤0.01% of the portfolio and ranks #1110 among its holdings. This is a return to the name: DnB Asset Management previously reported a position in CRSP as recently as Q3 2024.
DnB Asset Management first reported a position in CRSP in Q3 2024 and has held it in 2 quarters since. The position peaked at $555K in Q3 2024. 503 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- DnB Asset Management held 4,038 shares of CRISPR Therapeutics worth $223K as of Q3 2026.
- CRISPR Therapeutics was a new DnB Asset Management position in Q3 2026.
- CRISPR Therapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q3 2026, its #1110 holding.
- DnB Asset Management first reported a position in CRISPR Therapeutics in Q3 2024 and has held it in 2 quarters since.
- DnB Asset Management's CRISPR Therapeutics position peaked at $555K in Q3 2024.
- 503 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on DnB Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.